37th week of 2012 patent applcation highlights part 49 |
Patent application number | Title | Published |
20120231957 | RICE CULTIVAR CL142-AR - A rice cultivar designated CL142-AR is disclosed. The invention relates to the seeds of rice cultivar CL142-AR, to the plants of rice CL142-AR, to methods for producing a rice plant produced by crossing the cultivar CL142-AR with itself or another rice variety, and to methods for controlling weeds in the vicinity of plants of rice cultivar CL142-AR, which comprises increased resistance to acetohydroxyacid synthase-inhibiting herbicides. The invention further relates to hybrid rice seeds and plants produced by crossing the cultivar CL142-AR with another rice cultivar. | 2012-09-13 |
20120231958 | OXIDE SUPERCONDUCTING BULK MAGNET MEMBER - An oxide superconducting bulk magnet member includes a plurality of bulk sections that have outer circumferences with outer circumferential dimensions different from each other and are disposed in a manner such that among the outer circumferences, an outer circumference in which the outer circumferential dimension is relatively large surrounds a small outer circumference; and interposed sections that are disposed between a pair of the bulk sections that are adjacent to each other, wherein a gap is formed between the bulk sections adjacent to each other, each of the bulk sections is an oxide bulk in which an RE | 2012-09-13 |
20120231959 | PERSONALIZED MEDICAL MANAGEMENT SYSTEM, NETWORKS, AND METHODS - Disclosed herein are systems and methods for the assignment of therapeutic pathways to members of a network of oncology. The systems and methods allow for storage of disparate information in a database and determine a uniform semantics for all of the stored information. In addition, the systems and methods allow for the calculation of treatment pathways based on patient information as well as publicly-available information relating to particular diseases, and for the refinement of those treatment pathways as new information is added. Robot-assisted genomic labs permit automated genetic testing, which is integrated with the system. | 2012-09-13 |
20120231960 | SYSTEMS AND METHODS FOR HIGH-THROUGHPUT DETECTION OF AN ANALYTE IN A SAMPLE - Provided are high-throughput detection systems. The systems include a magnetic sensor device, a magnetic field source and a reservoir plate that includes a plurality of fluid reservoirs. The magnetic sensor device includes a support with two or more elongated regions each having a magnetic sensor array disposed at a distal end. Also provided are methods in which the subject high-throughput detection systems find use. | 2012-09-13 |
20120231961 | METHODS AND SYSTEMS FOR SPORES DETECTION - Provided herein are methods and systems for the detection of spores in a sample which comprise permeabilizing a protein-based spore coat with a protein degrading agent comprising a non-ionic detergent and in particular with a specific mixture of various protein degrading agents comprising a non-ionic detergent to allow contact of spore nucleic acids with fluorescent reagents suitable for detection. | 2012-09-13 |
20120231962 | REAL-TIME PCR OF TARGETS ON A MICRO-ARRAY - The present invention relates to a method and apparatus for monitoring on a micro-array a PCR amplification of a nucleotide molecule being present in a solution. The method includes the steps of: providing a support having fixed upon its surface a microarray having at least a capture molecule being immobilized in specifically localized areas of the support and a reaction chamber; introducing a solution containing the nucleotide molecule into the reaction chamber and reagents for nucleotide molecule amplification and labelling; submitting the solution to at least 2 thermal cycles having at least 2 and preferably 3 different temperature steps in order to obtain labelled target nucleotide molecule by PCR amplification; performing at least a measurement of the labelled target nucleotide molecule in at least one thermal cycle by incubating the labelled target nucleotide molecule under conditions allowing a specific binding between the target nucleotide molecule and its corresponding capture molecule and measuring the light emission from the bound labelled target nucleotide molecule in response to excitation light with the solution being present in the chamber and containing the labelled target nucleotide molecule. The surface of emission for a localized area is between about 0.1 μm | 2012-09-13 |
20120231963 | BIOTIN-LABEL-BASED ANTIBODY ARRAY FOR HIGH-CONTENT PROFILING OF PROTEIN EXPRESSION - The biotin-label-based array methods of the present disclosure have several advantages over fluorescence label. Biotin-label can be used as signal amplification. Biotin is the most common method for labeling protein and the label process can be highly efficient. Furthermore, biotin can be detected using fluorescence-streptavidin and, therefore, visualized using laser scanner, or by using HRP-streptavidin imaged using chemiluminescence. The results of the present disclosure show that using biotin-label-based antibody arrays, most targeted proteins can be detected at pg/ml levels. Systems for identifying at least one biomarker characteristic of a cancer or a cancer cell comprise: an antibody array comprising at least one antibody species capable of capturing a biomarker characteristic of a cancer or a cancer cell; a system for biotinylating at least one biomarker of a biosample obtained from a subject human or animal; and a detectable biotin-binding polypeptide. | 2012-09-13 |
20120231964 | METHOD FOR SELECTING NUCLEIC ACIDS THAT BOND WITH HIGH-AFFINITY TO A TARGET - The invention relates to a method for selecting nucleic acids that bond with high affinity to a target molecule from a mixture of nucleic acids, comprising: a) loading a column with the target molecules, b) feeding the nucleic acids into a first end of the column, to create a defined volumetric flow of medium through the column, c) immobilizing the nucleic acids to the target molecule wherein an affinity of the nucleic acids to the target molecule decreases as the distance from the first end of the column increases, d) stopping the volumetric flow after a defined period of time, e) cutting the column into segments, and allocating a routing co-ordinate to each segment, and f) identifying and collecting nucleic acids that bond with a high affinity to the target molecule by desorbing the immobilized nucleic acids from at least one segment. | 2012-09-13 |
20120231965 | DRUG SELECTION FOR COLORECTAL CANCER THERAPY USING ANTIBODY-BASED ARRAYS - The present invention provides methods for selecting a suitable anticancer drug therapy, and for identifying and predicting response, for the treatment of colorectal cancer. The present invention also provides methods for monitoring the status of colorectal cancer and monitoring how a patient with colorectal cancer is responding to anticancer drug therapy. | 2012-09-13 |
20120231966 | LUNG CANCER DIAGNOSTIC ASSAY - A method for selecting a person at risk for lung cancer to undergo radiographic testing is provided. The method provides for the identification of markers for lung cancer in a population of patients that have not previously diagnosed with the disease. The markers identify autoantibodies present in a fluid sample of a patient who may not show other symptoms of lung cancer. | 2012-09-13 |
20120231967 | SEQUENTIAL ANALYSIS OF BIOLOGICAL SAMPLES - Methods for detecting multiple targets in a biological sample are provided. The methods includes contacting the sample with a first probe; physically binding the first probe to a first target; observing a first signal from the first probe; applying a chemical agent to modify the first signal; contacting the sample with a second probe; physically binding the second probe to a second target; and observing a second signal from the second probe. The methods disclosed herein also provide for multiple iterations of binding, observing, signal modification for deriving information about multiple targets in a single sample. An associated kit and device are also provided. | 2012-09-13 |
20120231968 | Comparative Genomic Hybridization Assays Using Immobilized Oligonucleotide Features and Compositions for Practicing the Same - Comparative genomic hybridization assays and compositions for use in practicing the same are provided. A characteristic of the subject comparative genomic hybridization assays is that solid support immobilized oligonucleotide feature elements, e.g., in the form of an array, are employed. Specifically, at least first and second nucleic acid populations prepared from genomic templates are contacted with a plurality of distinct oligonucleotide feature elements immobilized on a solid support surface and the binding of the at least first and second populations is then evaluated. Also provided are kits for use in practicing the subject methods. | 2012-09-13 |
20120231969 | PROTEIN ARRAYS AND USES THEREOF - Illustrative embodiments herein disclosed relate to protein arrays, methods for making the arrays and methods for using them, among others. In some embodiments known proteins representing at least 50% of the loci in the human genome are arrayed in known positions on a support. In some embodiments arrays are made of proteins purified from cell lysates by affinity binding to the support. In some embodiments protein arrays are used to decode the binding specificity of antibodies. In some embodiments protein arrays are used to diagnose auto-immune disorders. Many other embodiments and general features are disclosed. | 2012-09-13 |
20120231970 | COLON CANCER MARKER AND METHOD FOR TESTING FOR COLON CANCER - Provided are a micro RNA which can be used as a colon cancer marker, a method for testing for colon cancer which uses the micro RNA which can be used as a colon cancer marker, and a test kit which can be used for the testing method. The colon cancer marker includes micro RNA molecules which are represented by any of the sequences 1 through 25. The method for testing for colon cancer in a subject involves preparing a sample, which contains a micro RNA molecule derived from the subject's colon tissue or colon cell, and detecting a micro RNA molecule represented by any of the sequences 1 through 25 present in the obtained sample. | 2012-09-13 |
20120231971 | METHOD AND APPARATUS FOR DETECTING ANALYTES - Provided is a method and apparatus for detecting analytes, in which an analyte-receptor complex that is formed by a coupling of an analyte and a receptor is separated from a free receptor that has not been coupled with the analyte, to then detect the analyte-receptor complex. The method and apparatus for detecting analytes does not only provide an effect of detecting various substances with a single sensor chip, but also provides advantages of detecting a particular object substance from a sample containing a number of substances and easily amplifying a signal. | 2012-09-13 |
20120231972 | Probe Compound for Detecting and Isolating Enzymes and Means and Methods Using the Same - The present invention relates to a probe compound that can comprise any substrate or metabolite of an enzymatic reaction in addition to an indicator component, such as, for example, a fluorescence dye, or the like. Moreover, the present invention relates to means for detecting enzymes in form of an array, which comprises any number of probe compounds of the invention which each comprise a different metabolite of interconnected metabolites representing the central pathways in all forms of life. Moreover, the present invention relates to a method for detecting enzymes involving the application of cell extracts or the like to the array of the invention which leads to reproducible enzymatic reactions with the substrates. These specific enzymatic reactions trigger the indicator (e.g. a fluorescence signal) and bind the enzymes to the respective cognate substrates. Moreover, the invention relates to means for isolating enzymes in form of nanoparticles coated with the probe compound of the invention. The immobilisation of the cognate substrates or metabolites on the surface of nanoparticles by means of the probe compounds allows capturing and isolating the respective enzyme, e.g. for subsequent sequencing. | 2012-09-13 |
20120231973 | METHOD AND APPARATUS PROVIDING ANALYTICAL DEVICE AND OPERATING METHOD BASED ON SOLID STATE IMAGE SENSOR - An analytical system-on-a-chip can be used as an analytical imaging device, for example, for detecting the presence of a chemical compound. A layer of analytical material is formed on a transparent layer overlying a solid state image sensor. The analytical material can react in known ways with at least one reactant to block light or to allow light to pass through to the array. The underlying sensor array, in turn, can process the presence, absence or amount of light into a digitized signal output. The system-on-a-chip may also include software that can detect and analyze the output signals of the device. | 2012-09-13 |
20120231974 | Self-Assembling High Density Ordered Patterned Biomolecule Array and Method for Making and Using the Same - A method for fabricating a universal substrate for attaching biomolecules, including sequencing features and the resulting substrate. A method of direct detection of analytes utilizes a Complementary Metal Oxide Semiconductor (CMOS) sensor with the substrate. | 2012-09-13 |
20120231975 | ADVANCED MIXING SYSTEM FOR INTEGRATED TOOL HAVING SITE-ISOLATED REACTORS - An integrated processing tool is described comprising a full-wafer processing module and a combinatorial processing module. Chemicals for use in the combinatorial processing module are fed from a delivery system including a set of first manifolds. An output of each first manifold is coupled to at least one mixing vessel. An output of each mixing vessel feeds more than one of a set of second manifolds. An output of each set of second manifolds feeds one of multiple site-isolated reactors of the combinatorial processing module. | 2012-09-13 |
20120231976 | Microfluidic Chip for High-Throughput Perfusion-Based Three-Dimensional Cell Culture - A microfluidic chip for three-dimensional cell culture with high-throughput perfusion includes an array of cell culture units, each unit including a cell culture medium inlet hole connecting to one cell culture medium tank, at least one micro-bioreactor, at least one microchannel and at least one medium collection and analysis tank. Each medium collection and analysis tank is connected to an air chamber with an air channel and the air chamber has negative pressure source holes to generate negative pressure to drive the culture medium. The microfluidic chip also includes an intermediate plate connected to the bottom surface of the roof, and two bottom plates detachably assembled at the bottom of the intermediate plate. The first and second bottom surfaces have micro-bioreactors and cylindrical recessed slots and the intermediate plate has corresponding holes to achieve the goal of three-dimensional cell culture using minimum experimental resources with high-throughput perfusion. | 2012-09-13 |
20120231977 | Thermal Insulating Fluids - Aqueous and substantially anhydrous fluids having particularly low thermal conductivities and variable densities are disclosed. The fluids include: one or more organic and/or inorganic salts and at least one aprotic polar organic solvent, a mixture of aprotic and erotic polar organic solvents, and/or a polar organic solvent having both prone and aprotic polar functional group linkages. The fluids optionally include one or more viscosifying agents and are free of cross-linking agents. Methods for formulating and using the fluids are also disclosed. | 2012-09-13 |
20120231978 | Permeability-Modifying Drilling Fluids and Methods of Use - Drilling fluids comprising a base fluid and a hydrophobically modified polymer. The hydrophobically modified polymer consisting of alkyl chains having a carbon chain length between about 4 and about 22 carbons bound to a hydrophilic polymer. The hydrophilic polymer (1) consists of a polymer backbone that contains polar heteroatoms, at least one of which is not a nitrogen atom, and at least a portion of the polar heteroatoms are functionalized with the alkyl chains; and, (2) comprises at least one hydrophilic polymer selected from the group consisting of a cellulose, a chitosan, a polyetheramine, a polyhydroxyetheramine, a polylysine, and a polysulfone. | 2012-09-13 |
20120231979 | Systems and Methods For Forming High Performance Compressible Objects - The present systems and methods utilize a polyamic acid solution as a precursor to form a polyimide bead having desired properties. The polyamic acid solution may be formed into a polyamic acid droplet. The polyamic acid droplet is then processed to form a polyamic acid bead, such as by extraction of solvent to concentrate the polyamic acid or by partial chemical imidization of the polyamic acid. The polyamic acid bead is then better able to retain its shape during subsequent processing steps, such as drying and pressurizing, before final thermal imidization. | 2012-09-13 |
20120231980 | WELL FLUID AND METHOD OF SERVICING A WELL - A well servicing fluid for reducing polymer degradation is disclosed. The well servicing fluid is formulated with components comprising: at least one free radical scavenger, with the proviso that the free radical scavenger is not erythorbate, lignin or lignin derivatives; at least one polymer and an aqueous based solvent. Methods for servicing a well employing well servicing fluids of the present disclosure are also disclosed. | 2012-09-13 |
20120231981 | Proppant Particles Formed From Slurry Droplets and Method of Use - Proppant material for hydraulic fracturing is provided. The particles of the proppant are formed by drip casting. A slurry of finely divided ceramic particles is flowed through nozzles and formed into droplets under the influence of vibration. Uniform sized, smooth surface, spherical green particles are formed. The green particles are dried and sintered to form the proppant. The proppant is used in the process of hydraulic fracturing of wells. | 2012-09-13 |
20120231982 | WELL TREATMENT METHODS AND SYSTEMS - A well treatment method includes drawing a solvent to a first pump, drawing a wetting liquid to a second pump, pumping the wetting liquid through a polymer mixer using the second pump, combining polymer with the wetting liquid to produce a slurry containing undissolved polymer, and combining the slurry with the solvent upstream from the first pump. Another well treatment method includes increasing dissolution time of the polymer by providing a buffering agent in the wetting liquid before combining the wetting liquid and the polymer. A well treatment system includes a polymer mixing subsystem with a mix loop having a mix loop inlet line from a first pump feed line and a mix loop outlet line back to the first pump feed line, the mix loop outlet line containing a polymer mixer. | 2012-09-13 |
20120231983 | ENGINE OIL ADDITIVE, ENGINE OIL AND METHOD OF ADDITION THEREOF - The engine oil additive contains multiple 300 to 500 nm-long polygonal plate-shaped silver crystal particles. The engine oil contains a base oil and the engine oil additive. The method of adding the additive to an engine oil includes adding multiple 300 to 500-nm-long polygonal plate-shaped silver crystal particles as an additive to the engine oil. | 2012-09-13 |
20120231984 | MARINE LUBRICATING OIL COMPOSITE ADDITIVE - A marine lubricating oil composite additive is provided. Based on the total weight of the composite additive, said marine lubricating oil composite additive comprises: 25-45% sulfonate detergent with superhigh base number, 40-60% phenolate detergent with low base number, 0-8% dispersing agent, 0-4% antiwear agent, and 10-20% Group I base oil with high viscosity index which is selected from the group consisting of 400SN, 500SN and 600SN. The composite additive of the present invention can satisfy the requirement of BOB system about the viscosity and base number, and can be blended with many system oils under a number of domestic and foreign brands so as to provide cylinder lubricating oils with different base numbers. The composite additive of the present invention has good adaptability and excellent performances in terms of antiwear, antioxidization and high temperature detergency, which meet the requirement of marine engines about the performance of cylinder lubricating oils. | 2012-09-13 |
20120231985 | MARINE CYLINDER OIL COMPOSITE ADDITIVE - The present invention relates to a marine cylinder oil composite additive. Based on the total weight of the composite additive, said marine cylinder oil composite additive comprises: 15-25% sulfonate detergent with superhigh base number, 35-45% phenolate detergent with superhigh base number, 20-30% naphthenate detergent with superhigh base number, 0-8% dispersing agent, 0-4% antiwear agent, and 10-20% Group I base oil with high viscosity index which is selected from the group consisting of 400SN, 500SN and 650SN. | 2012-09-13 |
20120231986 | FUNCTIONAL FLUID COMPOSITION - The present invention provides a functional fluid composition comprising: a naphthenic bright stock base oil; and a Fischer-Tropsch derived base oil, wherein the functional fluid composition has a Viscosity Index (according to ASTM D 2270) of above 95. | 2012-09-13 |
20120231987 | CLEANING COMPOSITION CONTAINING POLYMER MICROEMULSION - A gelled cleaning composition is provided that includes a standard temperature and pressure (STP) liquid oil or STP malleable wax present from 0.1 to 9.9 total weight percent. An emulsifier is present from 0.01 to 10 total weight percent, along with an alkylene glycol present from 0.002 to 11 total weight percent. A microemulsion is present in the composition from 0.2 to 15 total weight percent. Water forms a majority of the composition such that the composition is monophasic for at least 4 months storage at 20° Celsius. The composition is well suited for use in a process to remove a lipophlic substance from hands or an inanimate substrate by applying the composition and after allow sufficient time for the substance to be softened or solubilized, removing the composition and at least a portion of the substance. Silicone gaskets, as well as other cured resins and paints are readily removed. | 2012-09-13 |
20120231988 | SKIN CLEANSING SYSTEM AND METHOD - A cleansing composition for cleansing skin, especially for removing grease from skin. A cleaning composition of the present invention may also be used in ready-to-use (or in-use) kits, such as two component kits, suitable for cleansing skin. | 2012-09-13 |
20120231989 | LIGHT DUTY LIQUID CLEANING COMPOSITIONS AND METHODS OF MANUFACTURE AND USE THEREOF - The invention encompasses liquid cleaning compositions, for example, dish washing liquids, and methods of their manufacture and use, which possess enhanced cleaning ability. The cleaning compositions of the invention include acidic light duty liquid cleaning compositions with low toxicity and antibacterial efficacy on surfaces, for example, hard surfaces. | 2012-09-13 |
20120231990 | SOLIDIFICATION MATRIX USING A CARBOXYMETHYL CARBOHYDRATE POLYMER BINDING AGENT - A cleaning composition includes a carboxymethyl carbohydrate polymer, sodium carbonate, and water. The carboxymethyl carbohydrate polymer, sodium carbonate, and water interact to form a hydrate solid. The solid cleaning composition exhibits little or no swelling even when heated to temperatures up to 120° C. | 2012-09-13 |
20120231991 | Cleaning Compositions With Amphoteric Polycarboxylate Polymers - Cleaning compositions and laundry detergents comprising amphoteric polymers are disclosed. The amphoteric polymers may be comb polymers having polycarboxylate backbones and polyalkoxylate tentacles. In particular, the amphoteric polymer includes: a cationic group structure unit derived from a cationic group-containing monomer; and a carboxyl structure unit derived from a carboxyl group-containing monomer. The cationic group structure unit may be present at a level of 1% to 99% by mass based on 100% by mass of all structure units derived from all monomers in the amphoteric polymer. The carboxyl structure unit may be present at a level of 1% to 99% by mass based on 100% by mass of all the structure units derived from all the monomers in the amphoteric polymer. The cleaning compositions have high anti-soil redeposition ability and solubility with surfactants. | 2012-09-13 |
20120231992 | DIMENSIONALLY STABLE SOLID RINSE AID - The present invention is a solid rinse aid composition and methods of making and using the same. The solid rinse aid composition generally includes sodium sulfate and urea as solidification agents and an effective amount of an alcohol ethoxylate compound sheeting agent component and an effective amount of defoamer component. The solid rinse aid composition may also incorporate a preservative system including sodium bisulfate. The solid rinse aid composition may be phosphate-free, aminocarboxylate-free, and GRAS if desired. | 2012-09-13 |
20120231993 | NEW SYNTHETIC ROUTE FOR THE PREPARATION OF ALPHA-AMINO BORONIC ACID DERIVATIVES via SUBSTITUTED ALK-1-YNES - The present invention relates in general to the field of organic chemistry and in particular to the preparation of α-amino boronic acid derivatives. | 2012-09-13 |
20120231994 | ANTAGONISM OF HUMAN FORMYL PEPTIDE RECEPTOR FOR TREATMENT OF DISEASE - The present invention is directed to modulators of eosinophilic and neutrophilic function and the use of such modulators for treatment of eosinophil-associated and neutrophil-associated diseases. | 2012-09-13 |
20120231995 | USE OF PYRROLOQUINOLINE COMPOUNDS TO KILL CLINICALLY LATENT MICROORGANISMS - There is provided the use of compounds of formula I | 2012-09-13 |
20120231996 | Phalloidin derivatives and methods for their synthesis - The invention provides a cyclomonomer having actin-binding activity. The cyclomonomer is of utility for the study of the molecular biology of actin polymerization. The cyclomonomer is also useful for the study of and treatment of the toxic effects of | 2012-09-13 |
20120231997 | RECOMBINANT HUMAN CC10 PROTEIN FOR TREATMENT OF INFLUENZA - Methods of using recombinant human CC10 (rhCC10), also known as recombinant human uteroglobin, to reduce virus titers in the tissues of patients, particularly influenza titers in lung tissues are provided. RhCC10 may be used as a therapeutic in the treatment, cure, or prevention of viral infection, particularly influenza infection. More particularly, methods, including broadly the critical dosage ranges of rhCC10, intravenous and intranasal route of administration, which may be administered to treat, cure or prevent influenza infection are provided. Further provided are compositions useful in the foregoing methods and in administering rhCC10 to humans. | 2012-09-13 |
20120231998 | ORGANIC COMPOUNDS AND THEIR USES - The present application describes organic compounds that are useful for the treatment, prevention and/or amelioration of human diseases. | 2012-09-13 |
20120231999 | PEPTIDIC GLP-2 AGONISTS - Novel GLP-2 analogs with improved pharmacokinetic properties are described as well as their use in the treatment of disease. | 2012-09-13 |
20120232000 | METHODS AND COMPOSITIONS FOR PROMOTING REGENERATION BY INCREASING INTRACELLULAR SODIUM CONCENTRATION - The invention provides methods and compositions for increasing the intracellular sodium concentration in a cell. | 2012-09-13 |
20120232001 | STABLE FORMULATIONS FOR PARENTERAL INJECTION OF PEPTIDE DRUGS - Stable formulations for parenteral injection of peptide drugs and methods of using such stable formulations are provided. In particular, the present invention provides stable formulations for parenteral injection of glucagon and methods of using such glucagon formulations to treat hypoglycemia, especially severe hypoglycemia in emergency situations. | 2012-09-13 |
20120232002 | SLOW-ACTING INSULIN PREPARATIONS - Aqueous pharmaceutical formulations with an insulin analog, comprising
| 2012-09-13 |
20120232003 | COMPOSITIONS AND METHODS FOR DIABETES TREATMENT - The present invention relates to methods and compositions for the treatment or prevention of type 2 diabetes by administering an effective amount of a melatonin receptor agonist to a human subject in need of such treatment or prevention. | 2012-09-13 |
20120232004 | Methods for Treating Autoimmune Disorders, and Reagents Related Thereto - The invention generally relates to improved methods for the treatment or prophylaxis in animal subjects (including humans) of autoimmune disorders including Type I diabetes, septic shock, multiple sclerosis, inflammatory bowel disease (IBD) and Crohn's disease. | 2012-09-13 |
20120232005 | LIPOPROTEIN COMPLEXES AND MANUFACTURING AND USES THEREOF - The present disclosure relates to lipoprotein complexes and lipoprotein populations and their use in the treatment and/or prevention of dyslipidemic diseases, disorders, and/or conditions. The disclosure further relates to recombinant expression of apolipoproteins, purification of apolipoproteins, and production of lipoprotein complexes using thermal cycling-based methods. | 2012-09-13 |
20120232006 | PRODUCTION OF POLYURETHANE FOAMS - The invention relates to a process for producing polyurethane foams, by frothing and drying mixtures of specific polyurethane dispersions and crosslinkers. | 2012-09-13 |
20120232007 | METHOD FOR PRODUCING PROTEINS IN PICHIA PASTORIS THAT LACK DETECTABLE CROSS BINDING ACTIVITY TO ANTIBODIES AGAINST HOST CELL ANTIGENS - Methods for producing proteins and glycoproteins in | 2012-09-13 |
20120232008 | PLGF-1 IN HOMODIMERIC FORM - The present invention relates to a new homodimeric form of recombinant PlGF-1, to a process for its preparation and to compositions containing it. | 2012-09-13 |
20120232009 | Methods for Treatment of Insulin-Like Growth Factor-1 Deficiency - The present invention provides a method comprising administering to a patient suffering from an endocrine disorder characterized by partial endogenous growth hormone activity or signaling an amount of insulin-like growth factor-1 (IGF-1) and an amount of growth hormone (GH) that in combination are effective to improve growth or metabolism in the patient, where the patient receives IGF-1 in a single daily administration and receives GH in a single daily administration, and where the single administrations are administered to the patient substantially contemporaneously each day. | 2012-09-13 |
20120232010 | Compositions and Methods for Treating Bladder Cancer - The present invention provides methods and compositions for treating bladder cancer. In particular, the present invention provides a fusion protein comprising a toxin moiety that is linked to an epithelial growth factor (EGF) moiety. The toxin moiety and the EGF moiety can be linked optionally via a linker. Typically, the fusion protein is administered intravesically into the cancerous bladder. | 2012-09-13 |
20120232011 | Use of Rapamycin and Rapamycin Derivatives for the Treatment of Bone Loss - The present invention relates to a new use of rapamycin and rapamycin derivatives. | 2012-09-13 |
20120232012 | COMPOSITIONS HAVING ANTIANGIOGENIC ACTIVITY AND USES THEREOF - The invention generally features compositions and methods that are useful for modulating blood vessel formation, as well as methods that provide for the systematic and efficient identification of angiogenesis modulators. As described in more detail below, a systematic computational methodology based on bioinformatics was used to identify novel peptide modulators of angiogenesis that have been characterized in vitro and/or in vivo. | 2012-09-13 |
20120232013 | CROSS-LINKED GELATIN COMPOSITION COMPRISING A WETTING AGENT - Disclosed is a biocompatible, hemostatic, cross-linked gelatin composition comprising a biocompatible material comprising cross-linked gelatin and a sufficient amount of wetting agent to permit uniform wetting of the sponge in the presence of an aqueous solution. | 2012-09-13 |
20120232014 | ANTITHROMBOTIC COMPOUNDS - A soluble compound for preventing or reducing blood coagulation comprising an antithrombotic agent and a membrane binding element, wherein the antithrombotic agent has a weight of less than about 5,000 daltons. Also disclosed is a soluble compound for preventing or reducing blood coagulation comprising an anticoagulant joined to a membrane binding element via a joining element, wherein the joining element between the anticoagulant and the membrane binding element is less than about 10,000 daltons in weight. These compounds can be used in therapy and, in particular, in preventing or reducing blood coagulation. As a result, a method of treatment is provided comprising administering an effective amount of the compounds to a subject to prevent or reduce blood coagulation as well as a method of perfusing an organ, tissue or cell comprising contacting the compounds with the organ, tissue or cell to prevent or reduce blood coagulation. Also disclosed is an organ, tissue or cell which has been perfused with the compounds. | 2012-09-13 |
20120232015 | Novel N-Benzylamide Substituted Derivatives of 2-(Acylamido)acetic Acid and 2-(Acylamido)propionic Acids: Potent Neurological Agents - A first aspect of the invention is a compound (sometimes also referred to herein as an “active agent” or “active compound”) of Formula Ia, or more particularly Formula Ib, or a pharmaceutically acceptable salt or prodrug thereof. Compositions thereof and methods of using the same (e.g. for the treatment of a neurological disease) are also described. | 2012-09-13 |
20120232016 | METHOD AND SYSTEM TO DETECT AND DIAGNOSE ALZHEIMER'S DISEASE - Various embodiments provide methods for the detection, the diagnosis, and/or the prediction of disease onset of Alzheimer's disease. Methods for determining a state of Alzheimer's disease are provided. Accordingly, these methods can comprise the steps of placing a sample comprising at least one blood component onto a substrate, labeling the sample to identify at least one epigenetic marker and at least one of an inflammation marker and a cellular stress marker; determining an amount of the markers; performing a multivariate statistical analysis to produce an output value; comparing the output value to a reference value; and determining a state of Alzheimer's disease. | 2012-09-13 |
20120232017 | REDUCED VOLUME FORMULATION OF GLATIRAMER ACETATE AND METHODS OF ADMINISTRATION - A method for reducing frequency of relapses in a human patient afflicted with relapsing-remitting multiple sclerosis (RAMS) comprising administering to the patient 0.5 ml of an aqueous pharmaceutical solution of 20 mg glatiramer acetate and 20 mg mannitol and an injection assisting device for facilitating the administration of the pharmaceutical solution. | 2012-09-13 |
20120232018 | POLYCARBONATES FOR DELIVERY OF DRUGS AND METHODS OF PREPARATION THEREOF - A cyclic carbonate monomer has the formula (2): | 2012-09-13 |
20120232019 | Compositions and Methods for Treatment of Eye Disorders - The present invention provides compounds and methods for the treatment of LFA-1 mediated diseases. In particular, LFA-1 antagonists are described herein and these antagonists are used in the treatment of LFA-1 mediated diseases. One aspect of the invention provides for diagnosis of an LFA-1 mediated disease and administration of a LFA-1 antagonist, after the patient is diagnosed with a LFA-1 mediated disease. In some embodiments, the LFA-1 mediated diseases treated are dry eye disorders. Also provided herein are methods for identifying compounds which are LFA-1 antagonists. | 2012-09-13 |
20120232020 | METHOD OF IMPROVING TRANSPLANT FUNCTION USING SOLUBLE COMPLEMENT RECEPTOR TYPE I (sCR1) - A method is disclosed for inhibiting complement activation in brain-dead organ donors, particularly kidney donors, which leads to improvement of organ function of transplanted organs in recipients. The method involves administration of a complement inhibitory protein, specifically a soluble complement receptor type I (sCR1) polypeptide to the donor prior to harvesting the organ for transplant. | 2012-09-13 |
20120232021 | PEPTIDE LINKERS FOR POLYPEPTIDE COMPOSITIONS AND METHODS FOR USING SAME - Disclosed herein are novel peptide linkers and polypeptide compositions comprising the linkers (e.g., chimeric polypeptides) and methods of using the polypeptide compositions. The compositions and methods are particularly useful for targeting/delivering a polypeptide or protein of interest (e.g., a therapeutic polypeptide) to a cell, tissue or organ of interest in order to treat various diseases or disorders (e.g., lysosomal storage disorders). | 2012-09-13 |
20120232022 | BOTULINUM TOXIN TREATMENTS - A method and composition for treating a patient suffering from a disease, disorder or condition and associated pain include the administration to the patient of a therapeutically effective amount of a neurotoxin selected from a group consisting of Botulinum toxin types A, B, C, D, E, F and G. | 2012-09-13 |
20120232023 | WHEY PROTEIN PRODUCT AND A METHOD FOR ITS PREPARATION - The invention relates to a whey protein product having a ratio of whey protein to casein in the range from about 90:10 to about 50:50 and the total protein content of at least 20% on dry matter basis, and a method for its preparation. The product has a favourable amino acid composition and is especially suitable for athletes. | 2012-09-13 |
20120232024 | THERAPEUTIC USES OF SOLUBLE ALPHA-KLOTHO - The present invention relates to therapeutic uses of soluble alpha-Klotho. | 2012-09-13 |
20120232025 | SAFENER DRUG COMBINATIONS FOR USE WITH NMDA ANTAGONIST DRUGS - Prolonged administration of subanesthetic dosages of ketamine, which suppresses activity at NMDA receptors, can provide a damaged central nervous system with an opportunity to use its innate healing processes to “reset” NMDA receptors which were pushed into an unwanted hyper-sensitized state by unusually high activity. However, such treatments can cause permanent brain damage, if the ketamine dosage is too heavy or prolonged. Certain types of “safener” drugs have previously been identified, which can block or at least reduce those unwanted side effects. It is disclosed that if two classes of safener drugs are combined, which will simultaneously suppress activity at both (i) muscarinic acetylcholine receptors, and (ii) the kainate and AMPA classes of glutamate receptors, those safener drug combinations can provide exceptionally potent and reliable safening activity, which can enable the safe use of potent NMDA antagonist drugs for a number of highly beneficial purposes. | 2012-09-13 |
20120232026 | SPIROCYCLIC ISOXAZOLINE DERIVATIVES AS ANTIPARASITIC AGENTS - The invention recites spirocyclic isoxazoline derivatives of Formula (V.1), Formula (V.2), Formula (V.1.1), and Formula (1) | 2012-09-13 |
20120232027 | CROSSLINKING BRANCHED MOLECULE THROUGH THIOL-DISULFIDE EXCHANGE TO FORM HYDROGEL - In a process for forming a hydrogel, a precursor crosslinkable through disulfide bonds for forming the hydrogel is provided in a solution. The precursor comprises a branched molecular structure, which comprises a plurality of branches. At least three of the branches each comprises a disulfide bond. The pH in the solution is adjusted to initiate thiol-disulfide exchange in the precursor, thus crosslinking the precursor through disulfide bonds formed by thiol-disulfide exchange. After the precursor is sufficiently crosslinked to form a hydrogel, the pH in the solution is adjusted to inhibit further thiol-disulfide exchange in the hydrogel. Further, a hydrogel matrix may comprise a polymer substantially crosslinked through disulfide bonds. The polymer may comprise a hydrophobic poly(amido amine) core and an amino-functionalized hydrophilic shell. | 2012-09-13 |
20120232028 | Bicyclic Compound, Production and Use Thereof - The present invention provides a new cyclic compound having a CCR antagonist activity, especially a CCR5 antagonist activity, and the use thereof. The compound of the present invention is represented by the formula: | 2012-09-13 |
20120232029 | 2',4'-SUBSTITUTED NUCLEOSIDES AS ANTIVIRAL AGENTS - Embodiments of the invention are to compounds, methods, and compositions for use in the treatment of viral infections. More specifically embodiments of the invention are 2′,4′-substituted nucleoside compounds useful for the treatment of viral infections, such as HIV, HCV, and HBV infections. | 2012-09-13 |
20120232030 | HEAT STABLE HYALURONIC ACID COMPOSITIONS FOR DERMATOLOGICAL USE - The disclosure provides hyaluronic acid (HA) gel formulations and methods for treating the appearance of the skin. The formulations hyaluronic acid and at least one additional ingredient. Methods for treating lines, wrinkles, fibroblast depletions, and scars with the disclosed composition are provided as well. | 2012-09-13 |
20120232031 | INJECTABLE FORMULATIONS FOR INTRA-ARTICULAR OR PERI-ARTICULAR ADMINISTRATION - Described herein are injectable formulations for intra-articular or peri-articular administration, wherein the formulation is administered to treat joint pain. An injectable formulation for intra-articular or peri-articular administration disclosed herein comprises a therapeutically-effective amount of a leukotriene synthesis inhibitor compound formulated for intra-articular or peri-articular administration. | 2012-09-13 |
20120232032 | ANTIMICROBIAL AND/OR EPITHELIAL CELL GROWTH STIMULATING SUBSTANCE AND COMPOSITION AND TISSUE DRESSING MATERIAL - A chitosan for use in an antimicrobial treatment of a patient's tissue and a pharmaceutical composition comprising a chitosan for use in an antimicrobial treatment of a patient's tissue. A method of treating a microbial infection, the method comprising the step of administering to a patient an effective amount of a chitosan and an aqueous solution comprising chitosan. A chitosan or a pharmaceutical composition comprising a chitosan for use in an epithelial cell growth stimulating treatment of a patient's tissue. A method of stimulating the growth of epithelial cells the method comprising the step of administering to a patient or to an epithelial cells containing cell culture an effective amount of a chitosan or a pharmaceutical composition comprising chitosan. A tissue dressing material characterized in that it consists of chitosan or a chitosan comprising composition. | 2012-09-13 |
20120232033 | AMINES OR AMINO ALCOHOLS AS GLYT1 INHIBITORS - The invention relates to the use of compounds of formula I | 2012-09-13 |
20120232034 | VESICULAR FORMULATIONS - Disclosed herein are vesicular formulations that include one or more phospholipids and one or more surfactants and in certain embodiments the use of such formulations for the delivery of fatty acids for the treatment of disorders such as, fatty acid metabolic disorders, including essential fatty acid deficiency; pain or inflammation or osteoarthritis, more specifically for the treatment of deep tissue pain; asthma, bronchospasm, atherothrombatic cardiovascular disorders, avenous thrombatic disorders, inflammatory dermatoses disorders (e.g., atopic eczema, dishydrotic hand eczema, plaque type psoriasis, seborrheic eczema, and acne vulgaris), and dysmenorrhea. | 2012-09-13 |
20120232035 | Bicyclic pyrimidinones and uses thereof - The present invention provides a compound of Formula I or a pharmaceutically acceptable derivative, salt or prodrug thereof. Further provided is a method of treatment or prophylaxis of a viral infection in a subject comprising administering to said subject an effective amount of a compound of Formula I or a pharmaceutically acceptable derivative, salt or prodrug thereof. A pharmaceutical composition or medicament comprising a compound of Formula I is also provided. | 2012-09-13 |
20120232036 | Prodrugs of 2,4-Pyrimidinediamine Compounds and Their Uses - The present disclosure provides prodrugs of biologically active 2,4-pyrimidinediamine compounds, compositions comprising the prodrugs, intermediates and methods for synthesizing the prodrugs and methods of using the prodrugs in a variety of applications. | 2012-09-13 |
20120232037 | TREATMENT OF OBESITY, METABOLIC SYNDROME, AND DIABETES WITH PROTEIN KINASE C INHIBITORS - Disclosed herein are methods for treating obesity, metabolic syndrome, diabetes, or a combination of these conditions. The methods include selecting a subject with obesity, metabolic syndrome, or diabetes and administering to the subject a therapeutically effective amount of a composition comprising a compound that specifically inhibits hepatic protein kinase C (PKC)-τ, thereby treating the obesity, metabolic syndrome, or diabetes in the subject. In some embodiments the compound that specifically inhibits hepatic PKC-τ includes a thio-gold compound (such as aurothiomalate, aurothioglucose, and auranofin) or a derivative thereof, or a pharmaceutically acceptable salt thereof. In other embodiments, the compound that specifically inhibits hepatic PKC-τ includes 1H-imidazole-4-carboxamide, 5-amino-1-[2,3-dihydroxy-4-[(phosphonooxy)methyl]cyclopentyl]-[1R-(1α,2β,3β,4α)] (ICAPP) or a derivative thereof, or a pharmaceutically acceptable salt thereof. | 2012-09-13 |
20120232038 | CRYSTALLINE FORMS OF (3R, 3AS, 6AR) - HEXAHYDROFURO [2,3-B] FURAN-3-YL (1S,2R) - (1-{4-[ (DIETHOXYPHOSPHORYL) METHOXY] PHENY1}-3-HYDROXY-4- [4-METHOXY-N- (2-METHYLPROPYL) BENZENESUL - FONAMIDO] BUTAN-2-YL) CARBAMATE - The present inventions provides crystalline forms of (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl (1S,2R)-(1-{4-[(diethoxyphosphoryl)methoxy]phenyl}-3-hydroxy-4-[4-methoxy-N-(2-methylpropyl)benzenesulfonamido]butan-2-yl)carbamate, methods of preparing the crystalline forms, pharmaceutical compositions containing the crystalline forms, and therapeutic uses thereof. | 2012-09-13 |
20120232039 | PRIMARY AMINE DIAZENIUMDIOLATE HETEROCYCLIC DERIVATIVES - A compound having the structure | 2012-09-13 |
20120232040 | MEDICATION FOR CLINICAL EXTENSIVELY-DRUG RESISTANT ACINETOBACTER BAUMANNII - A medication for | 2012-09-13 |
20120232041 | PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING ANGINA OR MYOCARDIAL INFARCTION INDUCED BY MYOCARDIAL ISCHEMIA - The present invention provides a pharmaceutical composition for the treatment and prophylaxis of angina and myocardial infarction, wherein a combination of a tea extract (catechins) and an antianginal drug are proved therapeutically potent in treating angina and mycocardial infarction induced from myocardial ischemia. The present invention also provides a use of a tea extract (catechins) in treating and preventing angina. | 2012-09-13 |
20120232042 | 17-HYDROXY-17-PENTAFLUORETHYL-ESTRA-4,9(10)-DIEN-11-ACYLOXYALKYLENE PHENYL DERIVATIVES, METHODS FOR THE PRODUCTION THEREOF AND USE THEREOF FOR TREATING DISEASES - The invention relates to 17-hydroxy-13-methyl-17-pentafluoroethyl-11-acyloxyalkylenephenyldodecahydrocyclopenta[a]phenanthren-3-one derivatives of the formula I with progesterone-antagonising action and to processes for preparation thereof, to use thereof for treatment and/or prophylaxis of disorders and to the use thereof for production of medicaments for treatment and/or prophylaxis of disorders, especially of fibroids of the uterus (myomas, uterine leiomyomas), endometriosis, heavy menstrual bleeds, meningiomas, hormone-dependent breast cancers and complaints associated with the menopause, or for fertility control and emergency contraception. | 2012-09-13 |
20120232043 | LUBIPROSTONE FOR OBSTETRICAL OR GYNECOLOGICAL APPLICATIONS - The invention relates to a method for terminating pregnancy or for menstrual induction, which method comprises administering a female subject with lubiprostone, preferably in combination of a progesterone receptor antagonist, such as mifepristone. | 2012-09-13 |
20120232044 | METHODS AND COMPOSITIONS FOR TREATING HYPERURICEMIA AND METABOLIC DISORDERS ASSOCIATED WITH HYPERURICEMIA - Methods and compositions for treating and/or preventing hyperuricemia or metabolic disorders associated with hyperuricemia comprising administering to a patient in need a therapeutically effective amount of diacerein, rhein, or a pharmaceutically acceptable salt, an analog, a prodrug, or an active metabolite thereof. | 2012-09-13 |
20120232045 | METHODS AND SYSTEMS FOR PROGNOSIS OF A PATIENT'S RESPONSE TO TREATMENT OF ANDROGENETIC SKIN DISORDERS - Methods and systems are described for prediction of a patient's response to a drug for treating androgenetic skin disorders such as alopecia, acne, and hirsutism. For a given drug such as anti-androgens and 5-alpha-reductase inhibitors, and a given dosage, the likely responsiveness of that drug and dosage may be determined, for example, by generating a set of patient scores based on a patient profile, including genetic sample information, and comparing that scores to a set of reference information. | 2012-09-13 |
20120232046 | METHOD AND KIT FOR REDUCING THE SYMPTOMS OF PERIPHERAL VASCULAR DISEASE - A method for reducing the symptoms of peripheral vascular disease and for improving peripheral circulation wherein a progestin is administered to a subject in need thereof. | 2012-09-13 |
20120232047 | SUBSTITUTED CLAVULANIC ACID - The present invention relates to compounds of formula I | 2012-09-13 |
20120232048 | METHOD FOR MODULATING GPR119 G PROTEIN-COUPLED RECEPTOR AND SELECTED COMPOUNDS - A method of modulating the activity of the GPR119 G protein-coupled receptor comprising administering to a mammalian patient in need thereof a therapeutically effective amount of at least one compound of Formula I or Formula IA and, optionally, an additional therapeutic agent. | 2012-09-13 |
20120232049 | PYRIDINE OR PYRIMIDINE DERIVATIVE HAVING EXCELLENT CELL GROWTH INHIBITION EFFECT AND EXCELLENT ANTI-TUMOR EFFECT ON CELL STRAIN HAVING AMPLIFICATION OF HGFR GENE - A pyridine or pyrimidine derivative represented by the formula (I) has an excellent HGFR inhibitory activity and exhibits strong cell proliferation inhibitory effect and anti-tumor effect against cancer cell lines with amplified HGFR gene. | 2012-09-13 |
20120232050 | Cyclic Inhibitors of 11 beta-Hydroxysteroid Dehydrogenase 1 - This invention relates to novel compounds of the Formula (I), (II), (II-A), (II-B), (II-C), (II-D), (III). (III-A). (IIII-B). (III-C). (III-D), (III-E) (IV), (IV-A), (IV-B). (IV-C), (IV-D). (V), (V-A), (V-B), (V-C), (V-D), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful for the therapeutic treatment of diseases associated with the modulation or inhibition of 11β-HSD1 in mammals. The invention further relates to pharmaceutical compositions of the novel compounds and methods for their use in the reduction or control of the production of cortisol in a cell or the inhibition of the conversion of cortisone to cortisol in a cell. | 2012-09-13 |
20120232051 | 3-AMINO-PYRIDINES AS GPBAR1 AGONISTS - This invention relates to novel 3-aminopyridines of the formula | 2012-09-13 |
20120232052 | ARYL CARBOXAMIDE DERIVATIVES AS TTX-S BLOCKERS - The present invention relates to aryl carboxamide derivatives of formula (I), wherein Ar | 2012-09-13 |
20120232053 | QUATERNARY AMMONIUM COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS - The invention provides compounds of the formula: | 2012-09-13 |
20120232054 | PYRROLOTRIAZINE COMPOUNDS - A compound of formula (I): | 2012-09-13 |
20120232055 | HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS - The present invention provides compounds, including resolved enantiomers, resolved diastereomers, solvates and pharmaceutically acceptable salts thereof, comprising the Formula I: | 2012-09-13 |
20120232056 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK - Disclosed herein are new heterocyclic compounds and compositions and their application as pharmaceuticals for the treatment of disease. Methods of inhibiting PAS Kinase (PASK) activity in a human or animal subject are also provided for the treatment of diseases such as diabetes mellitus. | 2012-09-13 |